Poniard Pharmaceuticals PARD Stock
Poniard Pharmaceuticals Price Chart
Poniard Pharmaceuticals PARD Financial and Trading Overview
| Poniard Pharmaceuticals stock price | 0.0001 USD |
| Previous Close | 1.0E-6 USD |
| Open | 1.0E-6 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 1.0E-6 - 1.0E-6 USD |
| 52 Week Range | 1.0E-6 - 0.01 USD |
| Volume | 10 USD |
| Avg. Volume | 0 USD |
| Market Cap | 29 USD |
| Beta (5Y Monthly) | 0.889084 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PARD Valuation Measures
| Enterprise Value | -337998 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.810005E-7 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.026 |
Trading Information
Poniard Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.889084 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.01 USD |
| 52 Week Low | 1.0E-6 USD |
| 50-Day Moving Average | 0.01 USD |
| 200-Day Moving Average | 0.01 USD |
PARD Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 1.5M |
| Float | N/A |
| Short Ratio | 2.56 |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | 47.72K |
| Short % of Float | 4.15% |
| Short % of Shares Outstanding | 3.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2010 |
| Most Recent Quarter (mrq) | September 30, 2011 |
| Next Fiscal Year End | December 31, 2011 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.026% |
| Return on Equity (ttm) | -210.37% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -13041000 USD |
| Net Income Avi to Common (ttm) | -16234000 USD |
| Diluted EPS (ttm) | -0.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.98M USD |
| Total Cash Per Share (mrq) | 1.32 USD |
| Total Debt (mrq) | 1.64M USD |
| Total Debt/Equity (mrq) | 52.62 USD |
| Current Ratio (mrq) | 0.756 |
| Book Value Per Share (mrq) | 2.079 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10457000 USD |
| Levered Free Cash Flow (ttm) | -4526500 USD |
Profile of Poniard Pharmaceuticals
| Country | United States |
| State | WA |
| City | Seattle |
| Address | 300 Elliott Avenue West |
| ZIP | 98119 |
| Phone | 206 281 7001 |
| Website | N/A |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Q&A For Poniard Pharmaceuticals Stock
What is a current PARD stock price?
Poniard Pharmaceuticals PARD stock price today per share is 0.0001 USD.
How to purchase Poniard Pharmaceuticals stock?
You can buy PARD shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Poniard Pharmaceuticals?
The stock symbol or ticker of Poniard Pharmaceuticals is PARD.
Which industry does the Poniard Pharmaceuticals company belong to?
The Poniard Pharmaceuticals industry is Biotechnology.
How many shares does Poniard Pharmaceuticals have in circulation?
The max supply of Poniard Pharmaceuticals shares is 3B.
What is Poniard Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Poniard Pharmaceuticals PE Ratio is now.
What was Poniard Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Poniard Pharmaceuticals EPS is -0.01 USD over the trailing 12 months.
Which sector does the Poniard Pharmaceuticals company belong to?
The Poniard Pharmaceuticals sector is Healthcare.